Angelo Leone Lombardo

List of Publications by Year in Descending Order

46 papers	4,316 citations	27 h-index	65 g-index
66 ext. papers	4,891 ext. citations	12.2 avg, IF	4.62 L-index

#	Paper	IF	Citations
46	DNA damage contributes to neurotoxic inflammation in Aicardi-Goutières syndrome astrocytes.. *Journal of Experimental Medicine*, **2022**, 219,	16.6	4
45	Lentiviral correction of enzymatic activity restrains macrophage inflammation in adenosine deaminase 2 deficiency. *Blood Advances*, **2021**, 5, 3174-3187	7.8	3
44	Laboratory-Scale Lentiviral Vector Production and Purification for Enhanced and Genetic Engineering. *Molecular Therapy - Methods and Clinical Development*, **2020**, 19, 411-425	6.4	7
43	Choice architecture-based prescribing tool for TB preventive therapy: a pilot study in South Africa. *Public Health Action*, **2020**, 10, 118-123	0.9	1
42	Choice architecture-based prescribing tool for TB preventive therapy: a pilot study in South Africa. *Public Health Action*, **2020**, 10, 118-123	0.9	1
41	Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis. *Frontiers in Immunology*, **2020**, 11, 1820	8.4	8
40	Gene Modification and Three-Dimensional Scaffolds as Novel Tools to Allow the Use of Postnatal Thymic Epithelial Cells for Thymus Regeneration Approaches. *Stem Cells Translational Medicine*, **2019**, 8, 1107-1122	6.9	17
39	TRPML1 links lysosomal calcium to autophagosome biogenesis through the activation of the CaMKKβ/VPS34 pathway. *Nature Communications*, **2019**, 10, 5630	17.4	58
38	Reversible immortalisation enables genetic correction of human muscle progenitors and engineering of next-generation human artificial chromosomes for Duchenne muscular dystrophy. *EMBO Molecular Medicine*, **2018**, 10, 254-275	12	21
37	Patient-Specific iPSC-Derived Endothelial Cells Provide Long-Term Phenotypic Correction of Hemophilia A. *Stem Cell Reports*, **2018**, 11, 1391-1406	8	33
36	T-cell defects in patients with germline mutations account for combined immunodeficiency. *Blood*, **2018**, 132, 2362-2374	2.2	59
35	Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1. *Science Translational Medicine*, **2017**, 9,	17.5	116
34	Genome editing for scalable production of alloantigen-free lentiviral vectors for gene therapy. *EMBO Molecular Medicine*, **2017**, 9, 1558-1573	12	31
33	Therapeutic gene editing in CD34 hematopoietic progenitors from Fanconi anemia patients. *EMBO Molecular Medicine*, **2017**, 9, 1574-1588	12	34
32	IL-10-Engineered Human CD4 Tr1 Cells Eliminate Myeloid Leukemia in an HLA Class I-Dependent Mechanism. *Molecular Therapy*, **2017**, 25, 2254-2269	11.7	28
31	NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease. *Blood*, **2017**, 130, 606-618	2.2	53
30	Inheritable Silencing of Endogenous Genes by Hit-and-Run Targeted Epigenetic Editing. *Cell*, **2016**, 167, 219-232.e14	56.2	257

29	Leukocytes recruited by tumor-derived HMGB1 sustain peritoneal carcinomatosis. *OncoImmunology* , **2016**, 5, e1122860	7.2	15
28	Targeted Gene Correction in Osteopetrotic-Induced Pluripotent Stem Cells for the Generation of Functional Osteoclasts. *Stem Cell Reports*, **2015**, 5, 558-68	8	19
27	481. Targeted Genome Editing in Mouse Hematopoietic Stem/Progenitor Cells (HSPC) To Model Gene Correction of SCID-X1. *Molecular Therapy*, **2015**, 23, S191	11.7	2
26	Targeted genome editing in human repopulating haematopoietic stem cells. *Nature*, **2014**, 510, 235-240	50.4	420
25	Loss of transcriptional control over endogenous retroelements during reprogramming to pluripotency. *Genome Research*, **2014**, 24, 1251-9	9.7	82
24	Genome editing: a tool for research and therapy: targeted genome editing hits the clinic. *Nature Medicine*, **2014**, 20, 1101-3	50.5	20
23	Targeted gene therapy and cell reprogramming in Fanconi anemia. *EMBO Molecular Medicine*, **2014**, 6, 835-48	12	54
22	NY-ESO-1 Single Edited T Cells to Treat Multiple Myeloma without Inducing GvHD. *Blood*, **2014**, 124, 308-308	2.2	
21	iPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF. *Nature Communications*, **2013**, 4, 2597	17.4	85
20	Targeted gene addition in human epithelial stem cells by zinc-finger nuclease-mediated homologous recombination. *Molecular Therapy*, **2013**, 21, 1695-704	11.7	52
19	TCR Gene Editing Achieved In a Single Round Of T Cell Activation Is Sufficient To Redirect T Cell Specificity and Prevent GvHD. *Blood*, **2013**, 122, 2898-2898	2.2	
18	The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity. *Neurobiology of Disease*, **2012**, 46, 41-51	7.5	136
17	Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. *Nature Medicine*, **2012**, 18, 807-815	50.5	333
16	Site-specific integration and tailoring of cassette design for sustainable gene transfer. *Nature Methods*, **2011**, 8, 861-9	21.6	261
15	An unbiased genome-wide analysis of zinc-finger nuclease specificity. *Nature Biotechnology*, **2011**, 29, 816-23	44.5	432
14	Genomic instability in induced stem cells. *Cell Death and Differentiation*, **2011**, 18, 745-53	12.7	112
13	TCR Gene Editing Results in Effective Immunotherapy of Leukemia without the Development of GvHD. *Blood*, **2011**, 118, 667-667	2.2	0
12	Editing Human Lymphocyte Specificity for Safe and Effective Adoptive Immunotherapy of Leukemia.. *Blood*, **2010**, 116, 3764-3764	2.2	

11	T Cell Receptor Gene Transfer into Naive and Central Memory Lymphocytes by Lentiviral Vectors for a Safe and Effective Adoptive Immune Therapy of Leukemia. *Blood*, **2008**, 112, 3529-3529	2.2	
10	Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. *Nature Biotechnology*, **2007**, 25, 1298-306	44.5	715
9	The immune response to lentiviral-delivered transgene is modulated in vivo by transgene-expressing antigen-presenting cells but not by CD4+CD25+ regulatory T cells. *Blood*, **2007**, 110, 1788-96	2.2	29
8	A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. *Blood*, **2007**, 110, 4144-52	2.2	218
7	Limited transgene immune response and long-term expression of human alpha-L-iduronidase in young adult mice with mucopolysaccharidosis type I by liver-directed gene therapy. *Human Gene Therapy*, **2006**, 17, 1112-21	4.8	44
6	Limited Transgene Immune Response and Long-Term Expression of Human ?-L-Iduronidase in Young Adult Mice with Mucopolysaccharidosis Type I by Liver-Directed Gene Therapy. *Human Gene Therapy*, **2006**, 061017065132001	4.8	
5	Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector. *Human Gene Therapy*, **2005**, 16, 81-90	4.8	66
4	Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. *Blood*, **2004**, 103, 3700-9	2.2	183
3	In vitro gene therapy of mucopolysaccharidosis type I by lentiviral vectors. *FEBS Journal*, **2002**, 269, 2764-71		14
2	Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Nonobese diabetic/severe combined immunodeficient. *Blood*, **2002**, 100, 4391-400	2.2	76
1	Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. *Human Gene Therapy*, **2002**, 13, 243-60	4.8	213